Could a bone drug help women with anorexia? new study investigates

NCT ID NCT04779216

Completed Disease control Sponsor: Karen Klahr Miller, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether romosozumab, a drug that builds bone, can improve bone density in women with anorexia nervosa. Thirty women received either romosozumab or a placebo for 12 months, followed by a single dose of zoledronic acid. The goal was to see if bone density and structure improved, offering a potential way to prevent fractures in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: romosozumab (a bone-building drug) and zoledronic acid (a bone-strengthening drug)
What this could lead to: If successful, this could point toward a treatment to improve bone density and reduce fracture risk in women with anorexia nervosa.
What could go wrong: This is a small pilot study with only 30 participants, so results may not apply to everyone. The long-term benefits and risks are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANOREXIA NERVOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anorexia nervosa Bone Diseases, Metabolic eating disorder Feeding and Eating Disorders osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANOREXIA NERVOSA BONE DENSITY, LOW BONE LOSS EATING DISORDERS

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.